Preview

Офтальмология

Расширенный поиск

Ингибиторы карбоангидразы в лечении глаукомы. Обзор. Часть 2

https://doi.org/10.18008/1816-5095-2020-4-676-682

Полный текст:

Аннотация

Местные и системные ингибиторы карбоангидразы (ИКА) широко применяются в лечении глаукомы как препараты, эффективно снижающие офтальмотонус. В данной части обзора приводится характеристика системных ИКА, их побочные действия, пути их преодоления, а также противопоказания к использованию. Рассмотрены возможности применения ИКА при беременности. Особое внимание уделено антиоксидантным свойствам ИКА и перспективным разработкам гибридных форм на основе существующих ИКА в рамках многоцелевой стратегии в лечении глаукомы.

Об авторе

Н. И. Курышева
Медико-биологический университет инноваций и непрерывного образования ФГБУ ГНЦ РФ «Федеральный биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства России; Консультативно-диагностический отдел Центра офтальмологии Федерального медико-биологического агентства России
Россия

доктор медицинских наук, профессор, заведующая кафедрой;

руководитель консультативно-диагностического отдела,

ул. Гамалеи, 15, Москва, 123098



Список литературы

1. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a doubleblind, prospective study. Am. J. Respir. Crit. Care Med. 2006 Jan 15;173(2):234–237. DOI: 10.1164/rccm.200507-1035OC

2. Van Berkel M.A., Elefritz J.L. Evaluating off-label uses of acetazolamide. Am J Health Syst Pharm. 2018 Apr 15;75(8):524–531. DOI: 10.2146/ajhp170279

3. Leaf D.E., Goldfarb D.S. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J. Appl. Physiol. 2007 Apr;102(4):1313– 1322. DOI: 10.1152/japplphysiol.01572.2005

4. Supuran C.T. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(4):423–431. DOI: 10.1517/17425255.2016.1154534

5. Masini E., Carta F., Scozzafava A., Supuran C.T. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(6):705–716. DOI: 10.1517/13543776.2013.794788

6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Oct 2, 2017. Carbonic Anhydrase Inhibitors. PMID: 31643176

7. Ghorai S., Pulya S., Ghosh K., Panda P., Ghosh B., Gayen S. Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. Bioorg. Chem. 2020 Jan;95:103557. DOI: 10.1016/j.bioorg.2019.103557

8. Her Y., Kil M.S., Park J.H., Kim C.W., Kim S.S. Stevens-Johnson syndrome induced by acetazolamide. J. Dermatol. 2011 Mar;38(3):272–275. DOI: 10.1111/j.13468138.2010.00921.x

9. Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S155–S162. DOI: 10.1016/s0039-6257(99)00107-1

10. Silver L.H. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S141–S145. DOI: 10.1016/s0039-6257(99)00111-3

11. Michaud J.E, Friren B. International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(2):235–243. DOI: 10.1016/s0002-9394(01)00974-6

12. Barnebey H., Kwok S.Y. Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204–1212. DOI: 10.1016/s0149-2918(00)83063-5

13. Auger G.A., Raynor M., Longstaff S. Patient perspectives when switching from Cosopt® (dorzolamide-timolol) to AzargaTM (brinzolamide-timolol) for glaucoma requiring multiple drug therapy. Clin Ophthalmol. 2012;6:2059–2062. DOI: 10.2147/OPTH.S33254

14. Manni G., Denis P., Chew P. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with openangle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293–300. DOI: 10.1097/IJG.0b013e31818fb434

15. Newman-Casey P., Niziol L., Gillespie B. The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study Ophthalmology 2020 (article in press). DOI: 1016/j.ophtha.2019.10.022 1 ISSN 0161-6420/19

16. Robin A., Grover D. Compliance and adherence in glaucoma management Indian J Ophthalmol. 2011;59(Suppl 1):S93–S96. DOI: 10.4103/0301-4738.73693

17. Djafari F., Lesk M.R., Harasymowycz P.J., Desjardins D., Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18(3):238–243. DOI: 10.1097/IJG.0b013e3181815421

18. Altafini R., Scherzer M., Frezzotti P. Brinzolamide 1%/timolol versus dorzolamide 2%/ timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study. Clinical Ophthalmology 2015;9:2263–2270. DOI: 10.2147/OPTH.S88891

19. Lanzl I., Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291–298. DOI: 10.2147/OPTH.S16355

20. Hutnik С., Neima D., Ibrahim N. Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free COSOPT®) in patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology 2010;4:581–590.

21. Kwon J., Heo J., Kim H., Song J. Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/ timolol Korean J Ophthalmol 2015;29(5):344–350. DOI: 10.3341/kjo.2015.29.5.344

22. Pinto L., Vandewalle E., Gerlier L., Stalmans I. Improvement in Glaucoma Patient Quality of Life by Therapy Switch to Preservative-Free Timolol/Dorzolamide Fixed Combination Ophthalmologica 2014;231:166–171. DOI: 10.1159/000356468

23. Ozawa H., Azuma E., Shindo K., Higashigawa M., Mukouhara R., Komada Y. Transient renal tubular acidosis in a neonate following transplacental acetazolamide. Eur J Pediatr. 2001;160(5):321–322. DOI: 10.1007/pl00008441

24. Worsham F. Jr, Beckman E.N., Mitchell E.H. Sacrococcygeal teratoma in a neonate association with maternal use of acetazolamide. JAMA 1978;240 (3):251–252.

25. Weaver T.E., Scott W.J. Jr. Acetazolamide teratogenesis: interaction of maternal metabolic and respiratory acidosis in the induction of ectrodactyly in C57BL/6J mice. Teratology 1984;30(2):195–202. DOI: 10.1002/tera.1420300207

26. Sethi H.S., Naik M., Gupta V.S. Management of glaucoma in pregnancy: risks and choices, a dilemma? Int J Ophthalmol 2016;9(11):1684–1690. DOI: 10.18240/ ijo.2016.11.24

27. Tangamornsuksan W., Lohitnavy M. Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. Pharmacogenomics J. 2019 Jun;19(3):286–294. DOI: 10.1038/s41397-018-0052-2

28. Sweeney K.R., Chapron D.J., Brandt J.L., Gomolin I.H., Feig P.U., Kramer P.A. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin. Pharmacol. Ther. 1986 Nov;40(5):518–524. DOI: 10.1038/clpt.1986.217

29. Schwenk M.H., St Peter W.L., Meese M.G., Singhal P.C. Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis. Pharmacotherapy. 1995 JulAug;15(4):522–527. PMID: 7479208

30. Liu Y., Zhao J., Zhong X., Wei Q. and Huang Y. Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2019;10:679. DOI: 10.3389/fphar.2019.00679

31. Hong E., Ahn S., Lim H. The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. BMC Ophthalmol 2017 Jul 12;17(1):124. DOI: 10.1186/s12886-017-0517-0

32. Suzuki T., Hayakawa K., Nakagawa Y. Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal Clinical Ophthalmology 2013:7:549–553.

33. Kawai K., Ohashi H., Suzuki T., Kitagaki H., Fujisawa S. Effect of anti-glaucoma drugs on inflammatory cytokine production by human and murine peripheral blood mononuclear cells. Nippon Ganka Gakkai Zasshi. 2010;114:669–677 (In Japanese).

34. Wolfensberger T.J. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol. 1999;97:387–397.

35. Mirshahi A., Tadayoni R., Mohsenzadeh N. Efficacy of adjuvant topical timolol– dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: A contralateral eye study. J.Curr Ophthalmol. 2019 Jun;31(2):168–171. DOI: 10.1016/j.joco.2019.01.008

36. Курышева Н.И., Азизова О.А., Пирязев А.П. Антирадикальная и антиоксидантная активность ингибиторов карбоангидразы для местного лечения глаукомы. Российский офтальмологический журнал 2011;4(3):55–61.

37. Курышева Н.И., Азизова О.А. Сравнительное исследование антиоксидантной активности комбинированных препаратов для местного лечения глаукомы. Российский офтальмологический журнал 2013;6(2):48–51.

38. Курышева Н.И., Азизова О.А., Пирязев А.П. Антиоксидантная активность фиксированнной комбинации дорзоламида с тимололом в аспекте нейропротекции при глаукоме. Офтальмология 2012;9(4):47–51. DOI: 10.18008/1816-5095-2012-4-47-51

39. Moreno V., Medina J., Pinazo R. Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma Eur J Ophthalmol 2009;19(4):565–571. DOI: 10.1177/112067210901900408

40. Sacca S., La Maestra S., Micale R. Ability of dorzolamide hydrochloride and timolol maleate to target mitochondria in glaucoma therapy Arch Ophthalmol. 2011 Jan;129(1):48–55. DOI: 10.1001/archophthalmol.2010.324

41. Nocentini A., Ferraroni M., Carta F., Ceruso M., Gratteri P., Lanzi C. Benzenesulfonamides incorporating flexible triazole moieties are highly effective arbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations. J Med Chem 2016;59(23):10692–e10704. DOI: 10.1021/acs.jmedchem.6b01389

42. Long D.D., Frieman B., Hegde S.S., Hill C.M., Jiang L., Kintz S. A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Bioorg Med Chem Lett 2013;23:939–e943. DOI: 10.1016/j.bmcl.2012.12.058

43. Chiaramonte N., Bua S., Ferraroni M., Nocentini A., Bonardi A., Bartolucci G. et al. 2-Benzylpiperazine: a new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in vivo activity for a new class of intraocular pressure lowering agents. Eur J Med Chem 2018;151:363–e375. DOI: 10.1016/j.ejmech.2018.04.002

44. Steele R.M., Benedini F., Biondi S., Borghi V., Carzaniga L., Impagnatiello F., et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of openangle glaucoma. Bioorg Med Chem Lett 2009;19:6565–e6570. DOI: 10.1016/j.bmcl.2009.10.036

45. Haefliger I., Flammer J. Nitric Oxide and Endothelin in the Pathogenesis of Glaucoma, Survey of Ophthalmology, 1999;43(1):551–558. DOI: 10.1016/s0039-6257(99)00026-0

46. Курышева Н.И. Гемоперфузия глаза и глаукома. Гринлайт. 2014. 138 с.

47. Курышева Н.И., Томилова И.К., Деев А.А., Назаров С.Б. Оксид азота в патогенезе катаракты и глаукомы. Вестник офтальмологии. 2001;5:5–7.

48. Mincione F., Benedini F., Biondi S., Cecchi A., Temperini C., Formicola G. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011;21:3216– e3221. DOI: 10.1016/j.bmcl.2011.04.046

49. Fabrizi F., Mincione F., Somma T., Scozzafava G., Galassi F., Masini E. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzym Inhib Med Chem 2012;27:138–e147. DOI: 10.3109/14756366.2011.597749

50. Bozdag M., Altamimi A.S.A., Vullo D., Supuran C.T., Carta F. State of the art on carbonic anhydrase modulators for biomedical purposes. Curr Med Chem 2018;25. DOI: 10.2174/0929867325666180622120625

51. Carta F., Aggarwal M., Maresca A., Scozzafava A., McKenna R., Masini E., Supuran C.T. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 2012;55(4):1721–1730. DOI: 10.1021/jm300031j


Для цитирования:


Курышева Н.И. Ингибиторы карбоангидразы в лечении глаукомы. Обзор. Часть 2. Офтальмология. 2020;17(4):676-682. https://doi.org/10.18008/1816-5095-2020-4-676-682

For citation:


Kurysheva N.I. Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part II. Ophthalmology in Russia. 2020;17(4):676-682. (In Russ.) https://doi.org/10.18008/1816-5095-2020-4-676-682

Просмотров: 83


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1816-5095 (Print)
ISSN 2500-0845 (Online)